Skip to main content

Table 3 Adverse events

From: ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes

Systemic, n° of patients (%) 3 (11.5%)
Local, n° of patients (%) 6 (23.1%)
 Pain 3 (11.5%)
 Bladder spasm 3 (11.5%)
 Dysuria 5 (15.4%)
 Hematuria 1 (3.8%)
 Difficult catheter insertion 1 (3.8%)
 Frequency/urgency 3 (11.5%)
 Nocturia 2 (7.7%)